A Case of Peritoneal Tuberculosis with Poncet's Disease in a Patient Treated with Infliximab.
- Author:
Hyo PARK
1
;
Chan Woong PARK
;
Ki Bang KIM
;
Min Ji LEE
;
Seok Jae ZEON
;
Seung Cheol SHIM
;
Mi Kyung LIM
;
Dong Hyuk SHEEN
Author Information
- Publication Type:Case Report
- MeSH: Antibodies, Monoclonal; Arthritis; Arthritis, Reactive; Humans; Joints; Mycobacterium; Peritonitis, Tuberculous; Rheumatic Diseases; Spondylitis, Ankylosing; Tuberculosis; Tumor Necrosis Factor-alpha; Infliximab
- From:Journal of Rheumatic Diseases 2011;18(1):55-59
- CountryRepublic of Korea
- Language:Korean
- Abstract: Infliximab is a chimeric mouse/human monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha) that is used worldwide to treat rheumatic disease. However, the reactivation of tuberculosis, including extrapulmonary menifestation, is a severe side effect of anti-TNF-alpha treatment. Mycobacterium tubercluosis causes two forms of joint involvement, TB arthritis and Poncet's disease. Poncet's disease is a rare aseptic form of arthritis, known as reactive arthritis in tuberculosis. We encountered a case of tuberculous peritonitis with Poncet's disease in a 38-yearold man with a history of ankylosing spondylitis that was treated with infliximab. We report this case with a review of the literature.
